Title:
VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
Document Type and Number:
WIPO Patent Application WO/2022/096612
Kind Code:
A3
Abstract:
Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin- induced lung fibrosis model or in an AAV-TGFβ1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin- induced lung fibrosis model or in an AAV-TGFβ1- induced lung fibrosis model.
Inventors:
KREUZ SEBASTIAN (DE)
KLEIN HOLGER (DE)
STROBEL BENJAMIN (DE)
KLEE STEPHAN (DE)
LAMLA THORSTEN (DE)
KAESTLE MARC (DE)
ICKENSTEIN LUDGER (DE)
KLEIN HOLGER (DE)
STROBEL BENJAMIN (DE)
KLEE STEPHAN (DE)
LAMLA THORSTEN (DE)
KAESTLE MARC (DE)
ICKENSTEIN LUDGER (DE)
Application Number:
PCT/EP2021/080697
Publication Date:
July 07, 2022
Filing Date:
November 04, 2021
Export Citation:
Assignee:
BOEHRINGER INGELHEIM INT (DE)
International Classes:
C12N15/113; A61K31/713
Domestic Patent References:
| WO2019086515A1 | 2019-05-09 |
Other References:
STROBEL ET AL: "Modeling pulmonary fibrosis by AAV-mediated TGFbeta1 Expression : a proof of concept study for AAV-based disease modeling and riboswitch-controlled vector production", INTERNET CITATION, 3 May 2018 (2018-05-03), XP002797006, Retrieved from the Internet [retrieved on 20200117]
SHASHI KUMAR GUPTA ET AL: "miR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity", MOLECULAR THERAPY, vol. 27, no. 1, 1 January 2019 (2019-01-01), US, pages 17 - 28, XP055658869, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2018.11.004
YAJIE GUO ET AL: "miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 59, no. 3, 1 October 2017 (2017-10-01), GB, pages 205 - 217, XP055658871, ISSN: 0952-5041, DOI: 10.1530/JME-16-0179
GHORBANI SAMIRA ET AL: "MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation", FRONTIERS IN IMMUNOLOGY, vol. 8, 19 July 2017 (2017-07-19), XP055826415, DOI: 10.3389/fimmu.2017.00758
HEWLETT JUSTIN C. ET AL: "Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets", MATRIX BIOLOGY, vol. 71-72, 1 October 2018 (2018-10-01), NL, pages 112 - 127, XP055825282, ISSN: 0945-053X, DOI: 10.1016/j.matbio.2018.03.021
SHASHI KUMAR GUPTA ET AL: "miR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity", MOLECULAR THERAPY, vol. 27, no. 1, 1 January 2019 (2019-01-01), US, pages 17 - 28, XP055658869, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2018.11.004
YAJIE GUO ET AL: "miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 59, no. 3, 1 October 2017 (2017-10-01), GB, pages 205 - 217, XP055658871, ISSN: 0952-5041, DOI: 10.1530/JME-16-0179
GHORBANI SAMIRA ET AL: "MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation", FRONTIERS IN IMMUNOLOGY, vol. 8, 19 July 2017 (2017-07-19), XP055826415, DOI: 10.3389/fimmu.2017.00758
HEWLETT JUSTIN C. ET AL: "Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets", MATRIX BIOLOGY, vol. 71-72, 1 October 2018 (2018-10-01), NL, pages 112 - 127, XP055825282, ISSN: 0945-053X, DOI: 10.1016/j.matbio.2018.03.021
Attorney, Agent or Firm:
UEXKÜLL & STOLBERG PARTNERSCHAFT VON PATENT- UND RECHTSANWÄLTEN MBB (DE)
Download PDF:
Previous Patent: NANOPARTICLE
Next Patent: OBTAINING HIGHLY CONCENTRATED HMO SOLUTIONS BY REVERSE OSMOSIS
Next Patent: OBTAINING HIGHLY CONCENTRATED HMO SOLUTIONS BY REVERSE OSMOSIS